Belleview Bioscience

Belleview Bioscience is a biotechnology company dedicated to the discovery and development of next-generation precision oncology therapeutics. The company focuses on the DNA Damage Response (DDR) pathway, utilizing synthetic lethality to target cancers with specific genetic deficiencies. Its lead candidate, BVB-101, is a highly selective small molecule inhibitor of Ubiquitin Specific Peptidase 1 (USP1), currently in late-stage preclinical development for the treatment of BRCA-mutant and other DDR-deficient tumors. Headquartered in San Diego, Belleview is led by industry veterans with extensive experience in oncology drug discovery and development. The company aims to address unmet needs in patients who have progressed on standard-of-care therapies, including PARP inhibitors.